Trial Profile
A multicenter phase II study of S-1+ramucirumab as first line treatment in elderly patients with advanced/recurrent gastric cancer(KSCC1701)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms KSCC1701
- 26 Mar 2022 Results published in the European Journal of Cancer
- 22 Jan 2022 Results of post-hoc analysis assessing the usefulness of G8 screening tool for stratifying the efficacy and safety of S-1 plus ramucirumab therapy to elderly patients with advanced/recurrent gastric cancer, presented at the 2022 Gastrointestinal Cancers Symposium.
- 08 Jun 2021 Primary endpoint (1-year survival rate) has been met, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.